Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ekoflor Complex
- Development stage
- Unknown
- Lead developer
- Vector-BiAlgam
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Ekoflor Complex (also known as Ekoflor) is a next-generation probiotic and enterosorbent dietary supplement developed by the Russian biotechnology company Vector-BiAlgam. It consists of a consortium of ten active strains of bifidobacteria (including *Bifidobacterium bifidum* and *Bifidobacterium longum*) and lactobacilli (including *Lactobacillus acidophilus*, *Lactobacillus plantarum*, and *Lactobacillus casei*) reversibly immobilized on a carbon-mineral enterosorbent carrier (SUMS-1). This unique co-formulation provides a dual therapeutic effect: the enterosorbent component selectively adsorbs and removes bacterial toxins, heavy metals, and xenobiotics from the gastrointestinal tract without disrupting water-salt balance, while the immobilized probiotic strains are protected from gastric acid, allowing them to safely reach the intestines to suppress pathogenic microflora, restore healthy microbiota, and support digestive and immunological functions. Ekoflor Complex is indicated for the treatment and prevention of antibiotic-associated dysbiosis, intestinal dysbacteriosis, food poisoning, chronic gastrointestinal diseases, acute and chronic hepatitis, allergies, immunodeficiencies, and the mitigation of side effects from oncology radiation and chemotherapy.
- Brand names
- Bifidum BAGComplex EkoflorEkoflorEkoflor ComplexTrilakt
- Other names
- Бифидум БАГТрилактЭкофлор
Beyond the preview
Go deeper on Ekoflor Complex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ekoflor Complex.